Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 · View on ClinicalTrials.gov ↗
Study Summary
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Conditions Studied
Interventions
- BIOLOGICAL MGC026 Dose Escalation
- BIOLOGICAL MGC026 Dose for Expansion
Study Locations (12)
Texas
- The University of Texas MD Anderson Cancer Center — Houston
- University of Texas Health Science Center at Houston — Houston
Other
- Oxford University Hospitals NHS Foundation Trust — Oxford
- The Royal Marsden NHS Foundation Trust — Sutton
California
- The Angeles Clinic and Research Institute — Los Angeles
Michigan
- START Midwest — Grand Rapids
New York
- START-New York Long Island — Lake Success
Oregon
- Providence Cancer Institute — Portland
Utah
- START Mountain Region — West Valley City
Queensland
- ICON Cancer Centre Wesley — Auchenflower
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06242470
The ClinicalTrials.gov registry entry for NCT06242470 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 40 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions — of which MGC026 Dose Escalation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06242470 reports 12 study locations spanning 10 distinct geographic areas — top geographies include Texas, Other, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06242470 about?
NCT06242470 is a clinical study titled "A Study of MGC026 in Participants With Advanced Solid Tumors". The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort exp...
What is the current status of trial NCT06242470?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-03-06. Estimated completion is 2028-10.
What conditions does trial NCT06242470 study?
This clinical trial studies the following conditions: Melanoma, Advanced Solid Tumor, Endometrial Cancer, Bladder Cancer, Non Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06242470?
The interventions under investigation include: MGC026 Dose Escalation (BIOLOGICAL), MGC026 Dose for Expansion (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06242470?
This trial is sponsored by MacroGenics, which has 40 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06242470 being conducted?
This trial has 12 study locations across California, Michigan, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.